Mona Eisermann
12 Papers
15 Citations
Mona Eisermann is an academic researcher. The author has contributed to research in topics: Medicine & Small interfering RNA. The author has an hindex of 3, co-authored 6 publications.
Chat about Author
Papers
Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Ansgar Santel,Manuela Aleku,Nadine Röder,Kristin Möpert,Birgit Durieux,Oliver Janke,Oliver Keil,Jens Endruschat,Sibylle Dames,Christian Lange,Mona Eisermann,Kathrin Löffler,Melanie Fechtner,Gerald Fisch,Christiane Vank,Ute Schaeper,Klaus Giese,Jörg Kaufmann +17 more
TL;DR: Intravenous administration of Atu027 prevents pulmonary metastasis and provides evidence that an increase in VE-cadherin protein levels as a downstream result of PKN3 target gene inhibition may change endothelial function, resulting in reduced colonization and micrometastasis formation.
98
Delivery of Therapeutic siRNA to the Lung Endothelium via Novel Lipoplex Formulation DACC
Volker Fehring,Ute Schaeper,Katharina Ahrens,Ansgar Santel,Oliver Keil,Mona Eisermann,Klaus Giese,Jörg Kaufmann +7 more
TL;DR: Development and in vivo characterization of a novel siRNA delivery system (DACC lipoplex) suitable for modulating target gene expression specifically in the lung vasculature and repeated treatment with DACC/siRNA(CD31) reduced formation of lung metastases and increased life span in a mouse model of experimental lung metastasis.
94
Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.
David Rider,Mona Eisermann,K Löffler,M Aleku,Daniel I. Swerdlow,Sibylle Dames,Judith Hauptmann,Eliot Morrison,Marie Lindholm,Steffen Schubert,G. Campion +10 more
TL;DR: SLN360 as discussed by the authors is a GalNAc-conjugated siRNA targeting LPA, designed to address the unmet medical need of LPA knockdown in primary hepatocytes.
44
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Jim Vadolas,Garrett Z. Ng,Kai Kysenius,Peter J. Crouch,Sibylle Dames,Mona Eisermann,Tiwaporn Nualkaew,Shahla Vilcassim,Ute Schaeper,George Grigoriadis +9 more
TL;DR: In this article, a small interfering RNA (siRNA) conjugate was used for hepatic targeting of transmembrane serine protease 6 (TMPRSS6) in β-thalassaemia mice.
Targeting Protein S Using Small Interfering RNA Is Well Tolerated and Protects Mice with Hemophilia a from Acute Hemarthrosis
Raja Prince,Ute Schaeper,Sibylle Dames,Sara Calzavarini,Claudia Quarroz,Maria Desiré Reina Caro,Astrid Chanfon Bätzner,Kathrin Löffner,Mona Eisermann,Anne Angelillo-Scherrer +9 more
TL;DR: In a murine model for hemophilia A (F8-/- mice) the intrinsically-activated test using ellagic acid (INTEM) assessed by rotative thromboelastometry (ROTEM®) was improved by treatment with GalNAc-PS siRNA, supporting that GalNA c-RNA treatment can be safe.
6